{
    "nct_id": "NCT06617286",
    "official_title": "MAC-CAR: a Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults with Poor-Risk Classical Hodgkin Lymphoma (cHL)",
    "inclusion_criteria": "* Age between ≥ 6 and ≤ 29.99 years at the time of consent.\n* Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)\n* Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:\n\nInduction failure Progressive disease Disease relapse (1st, 2nd or 3rd)\n\n* Confirmatory re-biopsy of relapse/refractory/persistent CD30+ cHL prior to study entry.\n* Risk Factors: Patient must meet 2 or more of the established risk factors:\n\nPerformance score (Karnofsky/Lansky) <;90% Time from diagnosis to first relapse of <1 year Extra nodal involvement at the time of relapse/progression High baseline metabolic tumor volume (MTV, >60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 29 Years",
    "exclusion_criteria": "* not meeting the inclusion criteria",
    "miscellaneous_criteria": ""
}